Voxalatamab  (Synonyms: JNJ-63898081; JNJ-081)

Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

CD3E & FOLH1

Voxalatamab can bind to PSMA-expressing tumor cells and CD3-expressing T cells to overcome immunosuppression and promote antitumor activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

916  [NCBI] & 2346  [NCBI]

P07766 & Q04609

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.68 kDa

2411871-58-2

Liquid

Colorless to light yellow

[Voxalatamab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Ig(G4-kappa_G4-lambda2)

• 
  Immobilized Human CD3 epsilon/CD3e Protein (ECD, His Tag) can bind Voxalatamab. The EC₅₀ for this effect is 4.79 ng/mL.
• 
  Immobilized Human PSMA/FOLH1 Protein can bind Voxalatamab. The EC₅₀ for this effect is 47.87 ng/mL.
• 
  Flow cytometric analysis of 1×10⁶ Jurkat cells labelling CD3E (red) with Voxalatamab (HY-P99517). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa Isotype Control (HY-P99003, blue) was used as the isotype control.

• [1]. Lim EA, et al. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023 Jun;21(3):366-375.  [Content Brief]

  [2]. Jonas S Heitmann, et al. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers (Basel). 2021 Feb 1;13(3):549.  [Content Brief]